Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001607062-21-000156
Filing Date
2021-06-14
Accepted
2021-06-14 14:53:46
Documents
34
Period of Report
2021-04-30

Document Format Files

Seq Description Document Type Size
1 10-Q ngio043021form10q.htm 10-Q 250583
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 19805
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 17520
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 3648
5 EXHIBIT 32.2 ex32_2.htm EX-32.2 3874
12 GRAPHIC image_001.jpg GRAPHIC 5943
  Complete submission text file 0001607062-21-000156.txt   1286825

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE ngio-20210430.xml EX-101.INS 155598
7 XBRL SCHEMA FILE ngio-20210430.xsd EX-101.SCH 16183
8 XBRL CALCULATION FILE ngio-20210430_cal.xml EX-101.CAL 18606
9 XBRL DEFINITION FILE ngio-20210430_def.xml EX-101.DEF 61328
10 XBRL LABEL FILE ngio-20210430_lab.xml EX-101.LAB 98592
11 XBRL PRESENTATION FILE ngio-20210430_pre.xml EX-101.PRE 86575
Mailing Address 10102 USA TODAY WAY MIRAMAR FL 33025
Business Address 10102 USA TODAY WAY MIRAMAR FL 33025 (416) 364-2551
NUGENEREX IMMUNO-ONCOLOGY, INC. (Filer) CIK: 0001804585 (see all company filings)

EIN.: 043208418 | State of Incorp.: DE | Fiscal Year End: 0731
Type: 10-Q | Act: 34 | File No.: 000-56153 | Film No.: 211014222
SIC: 2834 Pharmaceutical Preparations